EX9 Stock Overview
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Exelixis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.52 |
| 52 Week High | US$34.34 |
| 52 Week Low | US$18.26 |
| Beta | 0.51 |
| 11 Month Change | 39.75% |
| 3 Month Change | 40.48% |
| 1 Year Change | 63.29% |
| 33 Year Change | 116.66% |
| 5 Year Change | 113.98% |
| Change since IPO | 67.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| EX9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.4% | -0.7% | -0.02% |
| 1Y | 63.3% | -17.2% | 8.2% |
Return vs Industry: EX9 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: EX9 exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| EX9 volatility | |
|---|---|
| EX9 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine EX9's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,310 | Mike Morrissey | www.exelixis.com |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis, Inc. Fundamentals Summary
| EX9 fundamental statistics | |
|---|---|
| Market cap | €9.77b |
| Earnings (TTM) | €448.39m |
| Revenue (TTM) | €2.00b |
21.8x
P/E Ratio4.9x
P/S RatioIs EX9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EX9 income statement (TTM) | |
|---|---|
| Revenue | US$2.08b |
| Cost of Revenue | US$78.00m |
| Gross Profit | US$2.00b |
| Other Expenses | US$1.54b |
| Earnings | US$466.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.64 |
| Gross Margin | 96.25% |
| Net Profit Margin | 22.43% |
| Debt/Equity Ratio | 0% |
How did EX9 perform over the long term?
See historical performance and comparison